Q-omics provides the consensus-scored GCH1 profile across patient tissues and cancer cell-line models. GCH1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GCH1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GCH1 RNA expression shows 18,835 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where GCH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCH1 survival associations across molecular data types. GCH1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCH1 RNA expression–survival associations across cancer types. High GCH1 expression shows unfavorable associations in UVM, LGG and ACC, but favorable associations in SKCM, BLCA and PAAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GCH1 RNA expression.
This table summarizes GCH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GCH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCH1 shows lower tumor expression in KIRC, KICH, KIRP and LIHC and higher tumor expression in STAD and UCEC. The KIRC box plot shows higher GCH1 RNA expression in normal versus tumor tissue (log2 FC = −0.835, t-test p < 0.001).
This table shows molecular features associated with GCH1 in patient tissues and cancer cell lines. In patient samples, GCH1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GCH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
